Phase I study of α-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer

Cancer Immunology, Immunotherapy

Volumn 57, Issue 3, 2008, Pages 337-345

  Uchida, Tetsuro ^a   Horiguchi, Shigetoshi ^a   Tanaka, Yuriko ^a   Yamamoto, Heizaburo ^a   Kunii, Naoki ^a   Motohashi, Shinichiro ^a   Taniguchi, Masaru ^b   Nakayama, Toshinori ^a   Okamoto, Yoshitaka ^a  

^a CHIBA UNIVERSITY   (Japan)

^b RIKEN Center for Integrative Medical Sciences   (Japan)

Author keywords

Galactosylceramide; Clinical trial; Immunotherapy; Nasal submucosa; NKT cell

Indexed keywords

ALPHA GALACTOSYLCERAMIDE;

ADULT; AGED; ANEMIA; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD; CANCER PATIENT; CANCER RECURRENCE; CELL ACTIVITY; CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG SAFETY; FEMALE; HEAD AND NECK CANCER; HUMAN; MALE; NATURAL KILLER T CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RATING SCALE; SUBMUCOSA;

ADULT; AGED; AGED, 80 AND OVER; ANTIGEN-PRESENTING CELLS; CELLS, CULTURED; FEMALE; GALACTOSYLCERAMIDES; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOTHERAPY; INTERFERON TYPE II; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE TRANSFUSION; MALE; MIDDLE AGED; NASAL MUCOSA; PHENOTYPE; RECURRENCE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 37349014075     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0373-5     Document Type: Article

References (34)

1. Haddad R, Wirth L, Posner M (2006) Emerging drugs for head and neck cancer. Expert Opin Emerg Drugs 11:461-467
2. Tsao AS, Garden AS, Kies MS, Morrison W, Feng L, Lee JJ, Khuri F, Zinner R, Myers J, Papadimitrakopoulou V, Lewin J, Clayman GL, Ang KK, Glisson BS (2006) Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. J Clin Oncol 24:4163-4169
3. Ledeboer QC, Velden LA, Boer MF, Feenstra L, Pruyn JF (2005) Physical and psychosocial correlates of head and neck cancer: an update of the literature and challenges for the future (1996-2003). Clin Otolaryngol 30:303-319
4. Kitahara S, Ikeda M, Inouye T, Matsunaga T, Yamaguchi K, Takayama E, Healy GB, Tsukuda M (1996) Inhibition of head and neck metastatic and/or recurrent cancer by local administration of multi-cytokine inducer OK-432. J Laryngol Otol 110:449-453
5. Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortes-Funes H, Hitt R, Gascon P, Amellal N, Harstrick A, Eckardt A (2005) Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 23:5568-5577
6. Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, D'Andrea G, Seidman A, Norton L, Gunnett K, Falcey J, Anderson V, Waksal H, Mendelsohn J (2000) Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 18:904-914
7. Bendelac A, Rivera MN, Park SH, Roark JH (1997) Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu Rev Immunol 15:535-562
8. Taniguchi M, Harada M, Kojo S, Nakayama T, Wakao H (2003) The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu Rev Immunol 21:483-513
9. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L (2004) NKT cells: what's in a name? Nat Rev Immunol 4:231-237
10. Godfrey DI, Kronenberg M (2004) Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest 114:1379-1388
11. Smyth MJ, Godfrey DI, Trapani JA (2001) A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2:293-299
12. Wilson SB, Delovitch TL (2003) Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity. Nat Rev Immunol 3:211-222
13. Porcelli SA, Modlin RL (1999) The CD1 system: antigen-presenting molecules for T cell recognition of lipids and glycolipids. Annu Rev Immunol 17:297-329
14. Brigl M, Brenner MB (2004) CD1: antigen presentation and T cell function. Annu Rev Immunol 22:817-890
15. Giaccone G, Punt CJ, Ando Y, Ruijter R, Nishi N, Peters M, von Blomberg BM, Scheper RJ, van der Vliet HJ, van den Eertwegh AJ, Roelvink M, Beijnen J, Zwierzina H, Pinedo HM (2002) A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 8:3702-3709
16. Seino K, Motohashi S, Fujisawa T, Nakayama T, Taniguchi M. (2006) Natural killer T cell-mediated antitumor immune responses and their clinical applications. Cancer Sci 97:807-812
17. +NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 103:383-389
18. Ishikawa A, Motohashi S, Ishikawa E, Fuchida H, Higashino K, Otsuji M, Iizasa T, Nakayama T, Taniguchi M, Fujisawa T (2005) A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 11:1910-1917
19. Motohashi S, Kobayashi S, Ito T, Magara KK, Mikuni O, Kamada N, Iizasa T, Nakayama T, Fujisawa T, Taniguchi M (2002) Preserved IFN-alpha production of circulating Valpha24 NKT cells in primary lung cancer patients. Int J Cancer 102:159-165
20. Motohashi S, Ishikawa A, Ishikawa E, Otsuji M, Iizasa T, Hanaoka H, Shimizu N, Horiguchi S, Okamoto Y, Fujii S, Taniguchi M, Fujisawa T, Nakayama T (2006) A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 12:6079-6086
21. Carnaud C, Lee D, Donnars O, Park SH, Beavis A, Koezuka Y, Bendelac A (1999) Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol 163:4647-4650
22. Eberl G, MacDonald HR (2000) Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells. Eur J Immunol 30:985-992
23. Smyth MJ, Crowe NY, Pellicci DG, Kyparissoudis K, Kelly JM, Takeda K, Yagita H, Godfrey DI (2002) Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide. Blood 99:1259-1266
24. Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman RM (2003) Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med 198:267-279
25. Ko SY, Ko HJ, Chang WS, Park SH, Kweon MN, Kang CY (2005) Alpha-galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. J Immunol 175:3309-3317
26. Bonneau M, Epardaud M, Payot F, Niborski V, Thoulouze MI, Bernex F, Charley B, Riffault S, Guilloteau LA, Schwartz-Cornil I (2006) Migratory monocytes and granulocytes are major lymphatic carriers of Salmonella from tissue to draining lymphnode. J Leukoc Biol 79:268-276
27. + natural killer T-cell activation by alpha-galactosylceramide. Int J Cancer 117:265-273
28. Osman Y, Kawamura T, Naito T, Takeda K, Van Kaer L, Okumura K, Abo T (2000) Activation of hepatic NKT cells and subsequent liver injury following administration of α-galactosylceramide. Eur J Immunol 30:1919-1928
29. Kaneko Y, Harada M, Kawano T, Yamashita M, Shibata Y, Gejyo F, Nakayama T, Taniguchi M (2000) Augmentation of Vα14 NKT cell-mediated cytotoxicity by interleukin 4 in an autocrine mechanism resulting in the development of concanavalin A-induced hepatitis. J Exp Med 191:105-114
30. + T cells preferentially accumulate in human liver. Eur J Immunol 29:2406-2413
31. Harada M, Seino K, Wakao H, Sakata S, Ishizuka Y, Kojo S, Nakayama T, Taniguchi M (2004) Down-regulation of the invariant Valpha 14 antigen receptor in NKT cells upon activation. Int Immunol 16:241-247
32. Crow NY, Uldrich AP, Kyparissoudis K, Hammond KJ, Hayakawa Y, Sidobre S, Keating R, Kronenberg M, Smyth MJ, Godfrey D1 (2003) Glycolipid antigen drives expansion and sustained cytokine production by NKT cells. J Immunol 171:4020-4027
33. Smyth MJ, Wallace ME, Nutt SL, Yagita H, Godfrey Dl, Hayakawa Y (2005) Sequential activation of NKT cells and NK cells provides effective immunotherapy of cancer. J Exp Med 201:1973-1985
34. Chang DH, Osman K, Connolly J, Kukreja A, Krasovsky J, Pack M, Hutchinson A, Geller M, Liu N, Annable R, Shay J, Kirchhoff K, Nishi N, Ando Y, Hayashi K, Hassoun H, Steinman RM, Dhodapkar MV (2005) Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med 201:1503-1517